FDA Lays Down Its First Rulebook for Testing Psychedelics

The agency issued its first guidance for clinical trials of psilocybin, LSD and MDMA, setting expectations without approving any drug.

The US Food and Drug Administration has published its first comprehensive guidance for studying psychedelic drugs in clinical trials, a document titled 'Psychedelic Drugs: Considerations for Clinical Investigations.' It covers substances including psilocybin, LSD and MDMA, and points to potential therapeutic uses in major depressive disorder, PTSD and substance use disorders. Importantly, the guidance changes no laws and approves no specific drug; LSD and MDMA remain Schedule I substances requiring formal assessments of abuse potential.

The document is candid about the problems these trials face. It flags 'functional unblinding' — the fact that participants and therapists usually can tell who received an active dose versus placebo — as a design challenge. It recommends studying patients for at least 12 weeks, and ideally monitoring for around a year, and pushes back on the assumption that one or two sessions deliver lasting relief. The FDA also calls for continuous observation by two trained monitors during sessions, cites long-term monitoring for possible heart valve problems tied to serotonin receptor activation, and says expected effects like hallucinations and euphoria should be logged as adverse events.

For mental health care, clear rules are what turn promising anecdotes into approvable, prescribable treatments. A shared regulatory path lets developers design trials the agency will accept, which is the precondition for these therapies eventually reaching patients at scale rather than staying in research limbo.

What to watch: the guidance is non-binding, and it remains unclear what additional safety and risk-management studies any approved drug would demand. No product is closer to market because of this document alone — only the road to one is now mapped.

Source: New Atlas